Baki 1998.

Methods	Setting: Turkey, paediatric outpatient clinic Length of intervention period: 3 weeks Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Masking: double blind Excluded: not stated Withdrawals: stated (none) Baseline characteristics: comparable FEV1 and methacholine bronchial responsiveness but no other demographic data presented Jadad score=3
Participants	43 children: 22M 21F Age range: 7‐17 years Inclusion criteria: Diagnosis of mild to moderate asthma Age 7‐17 years FEV (% predicted) > 70 Methacholine BHR (PC20 FEV1) < 12 mg/ml Exclusion criteria: Respiratory tract infection within last 4 weeks
Interventions	BUD: 200 mcg 2xdaily (400 mcg/d) Placebo: 2xdaily, device not stated Delivery device: not stated
Outcomes	FEV1(% predicted) Methacholine BHR (PC20 FEV1)
Notes	No reply from author to clarify details of randomisation method or delivery device. Individual patient methacholine challenge data was estimated from graph and log transformed. Nedocromil and salmeterol treatment arms were also used: results not considered in this meta‐analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear